ORAGENICS INC

For the period ended Dec 31, 2024. Filed Mar 14, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 14, 2025

OGEN$0.35+1.6%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

CONSOLIDATED BALANCE SHEETS

	December 31, 2024	December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$864,840	$3,483,501
Prepaid expenses and other current assets	607,670	382,273
Total current assets	1,472,510	3,865,774
Prepaid research and development expense	-	1,090,750
Operating lease right-of-use assets	-	9,811
Total assets	$1,472,510	$4,966,335
Liabilities and Shareholders’ (Deficit) Equity
Current liabilities:
Accounts payable and accrued expenses	$1,355,867	$1,475,667
Short-term notes payable	328,528	312,703
Operating lease liabilities	-	9,811
Total current liabilities	1,684,395	1,798,181
Shareholders’ (deficit) equity:
Preferred stock, no par value; 50,000,000 shares authorized; -0- and 5,417,000 Series A shares, -0- and 4,050,000 Series B shares, -0- and -0- Series C shares, 7,488,692 and 7,488,692 Series F shares outstanding at December 31, 2024 and December 31, 2023, respectively	-	1,592,723
Common stock, $0.001 par value; 350,000,000 shares authorized; 12,570,100 and 3,080,693 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively	12,570	3,081
Additional paid-in capital	216,561,717	207,790,604
Accumulated Deficit	(216,786,172)	(206,218,254)
Total shareholders’ (deficit) equity	(211,885)	3,168,154
Total liabilities and shareholders’ (deficit) equity	$1,472,510	$4,966,335

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.